Giles Wilson Acquires 105,838 Shares of Dr. Martens (LON:DOCS) Stock

Key Points

• Dr. Martens insider Giles Wilson purchased 105,838 shares of the company's stock at an average price of GBX 91, totaling approximately £96,312.58.
• On the same day, Wilson also sold 30,000 shares and bought 30,019 shares, maintaining a transaction trend that indicates active insider trading.
• Analysts have a mixed outlook on Dr. Martens, with a consensus rating of "Hold" and the target price reduced to GBX 6,000 by Royal Bank Of Canada.

Dr. Martens plc (LON:DOCS - Get Free Report) insider Giles Wilson purchased 105,838 shares of the company's stock in a transaction dated Monday, September 1st. The shares were bought at an average price of GBX 91 per share, for a total transaction of £96,312.58.

Giles Wilson also recently made the following trade(s):

• On Monday, September 1st, Giles Wilson sold 30,000 shares of Dr. Martens stock. The stock was sold at an average price of GBX 91, for a total value of £27,300.
• On Monday, September 1st, Giles Wilson acquired 30,019 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 91 per share, with a total value of £27,317.29.
• On Monday, September 1st, Giles Wilson sold 105,785 shares of Dr. Martens stock. The stock was sold at an average price of GBX 90, for a total value of £95,206.50.
• On Monday, August 11th, Giles Wilson acquired 194 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 77 per share, with a total value of £149.38.
• On Friday, July 11th, Giles Wilson acquired 194 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 77 per share, with a total value of £149.38.
• On Wednesday, June 11th, Giles Wilson acquired 189 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 79 per share, with a total value of £149.31.

Dr. Martens Stock Performance

DOCS stock traded up GBX 1.60 on Friday, reaching GBX 92.05. The company's stock had a trading volume of 54,296,586 shares, compared to its average volume of 2,190,337. Dr. Martens plc has a 52 week low of GBX 43.02 and a 52 week high of GBX 94.35. The company has a market capitalization of £888.82 million, a P/E ratio of 18,410.00, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The firm has a fifty day moving average of GBX 81.64 and a two-hundred day moving average of GBX 67.13. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13.

Dr. Martens (LON:DOCS - Get Free Report) last issued its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DOCS. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Dr. Martens in a report on Friday, July 11th. Peel Hunt raised Dr. Martens to a "buy" rating in a research note on Monday, August 18th. Finally, Royal Bank Of Canada decreased their price target on Dr. Martens from GBX 7,000 to GBX 6,000 and set a "sector perform" rating for the company in a research note on Monday, May 19th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Dr. Martens presently has a consensus rating of "Hold" and an average price target of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.